UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 72

Sortiert nach

Current concepts and management of glioblastoma

Annals of neurology, 2011-07, Vol.70 (1), p.9-21

2011

Volltextzugriff (PDF)

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

The Lancet (British edition), 2017-10, Vol.390 (10103), p.1645-1653

2017

Volltextzugriff (PDF)

ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

Radiotherapy and oncology, 2023-07, Vol.184, p.109663-109663, Article 109663

2023

Volltextzugriff (PDF)

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Journal of clinical oncology, 2013-11, Vol.31 (32), p.4085-4091

2013

Volltextzugriff (PDF)

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

The lancet oncology, 2014-09, Vol.15 (10), p.1100-1108

2014

Volltextzugriff (PDF)

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Neuro-oncology (Charlottesville, Va.), 2020-12, Vol.22 (12), p.1840-1850

2020

Volltextzugriff (PDF)

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Neuro-oncology (Charlottesville, Va.), 2017-08, Vol.19 (8), p.1119-1126

2017

Volltextzugriff (PDF)

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

Neuro-oncology (Charlottesville, Va.), 2021-09, Vol.23 (9), p.1547-1559

2021

Volltextzugriff (PDF)

Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study

Canadian Medical Association journal (CMAJ), 2012-04, Vol.184 (7), p.E373

2012

Volltextzugriff (PDF)

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

Journal of clinical oncology, 2010-10, Vol.28 (30), p.4601-4608

2010

Volltextzugriff (PDF)

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Journal of neuro-oncology, 2018-05, Vol.138 (1), p.163-171

2018

Volltextzugriff (PDF)

Adjustment and support needs of glioma patients and their relatives: serial interviews

Psycho-oncology (Chichester, England), 2013-06, Vol.22 (6), p.1299-1305

2013

Volltextzugriff (PDF)

Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity

Radiotherapy and oncology, 2009-12, Vol.93 (3), p.597-601

2009

Volltextzugriff (PDF)

Prospective audit showing improved patient-assessed skin toxicity with use of betamethasone cream for those at high risk of radiation dermatitis

Radiotherapy and oncology, 2016-10, Vol.121 (1), p.143-147

2016

Volltextzugriff (PDF)

International comparisons of survival from lung cancer: pitfalls and warnings

Nature clinical practice. Oncology, 2007-10, Vol.4 (10), p.570-577

2007

Volltextzugriff (PDF)

Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia

Frontiers in oncology, 2023-01, Vol.12, p.1075559-1075559

2023

Volltextzugriff (PDF)

Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer

Radiotherapy and oncology, 2003-01, Vol.66 (1), p.75-85

2003

Volltextzugriff (PDF)

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial

Journal of clinical oncology, 2016-06, Vol.34 (18_suppl), p.LBA2000-LBA2000

2016

Volltextzugriff (PDF)

Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma

Cochrane database of systematic reviews, 2019-08, Vol.8 (8), p.CD013047

2019

Volltextzugriff (PDF)

What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?

European journal of cancer (1990), 2007-08, Vol.43 (12), p.1802-1809

2007

Volltextzugriff (PDF)

Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?

Lung cancer (Amsterdam, Netherlands), 2009-06, Vol.64 (3), p.358-366

2009

Volltextzugriff (PDF)

"It changes everything": Understanding how people experience the impact of living with a lower-grade glioma

Neuro-oncology practice, 2024-06, Vol.11 (3), p.255-265

2024

Volltextzugriff (PDF)

Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG

Neuro-oncology practice, 2018-03, Vol.5 (1), p.10-17

2018

Volltextzugriff (PDF)

Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study

Neurology, 2014-08, Vol.83 (6), p.537

2014

Volltextzugriff (PDF)

Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation

Seminars in oncology, 2003-02, Vol.30 (1), p.26-37

2003

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(68)
Mit Volltextzugriff
(69)

Publikationsform

Artikel
(71)
Dissertationen
(1)

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(46)
Life Sciences & Biomedicine
(45)
Humans
(38)
Oncology
(33)
Middle Aged
(22)
Female
(21)
Male
(21)
Aged
(18)
Adult
(16)
Radiotherapy
(15)
Biological And Medical Sciences
(13)
Clinical Neurology
(13)
Medical Sciences
(13)
Neurosciences & Neurology
(13)
Tumors
(13)
Aged, 80 And Over
(10)
Hematology, Oncology And Palliative Medicine
(9)
Cancer
(8)
Disease-Free Survival
(8)
Radiology, Nuclear Medicine & Medical Imaging
(8)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Current concepts and management of glioblastoma

Interim results from the CATNON trial (EORTC study 26053-22054) of treatment with concurrent and adjuvant temozolomide for 1p/19q non-co-deleted anaplastic glioma: a phase 3, randomised, open-label intergroup study

ESTRO-EANO guideline on target delineation and radiotherapy details for glioblastoma

Dose-Dense Temozolomide for Newly Diagnosed Glioblastoma: A Randomized Phase III Clinical Trial

Cilengitide combined with standard treatment for patients with newly diagnosed glioblastoma with methylated MGMT promoter (CENTRIC EORTC 26071-22072 study): a multicentre, randomised, open-label, phase 3 trial

Pharmacokinetics, safety, and tolerability of olaparib and temozolomide for recurrent glioblastoma: results of the phase I OPARATIC trial

Is more better? The impact of extended adjuvant temozolomide in newly diagnosed glioblastoma: a secondary analysis of EORTC and NRG Oncology/RTOG

Prognostic significance of genome-wide DNA methylation profiles within the randomized, phase 3, EORTC CATNON trial on non-1p/19q deleted anaplastic glioma

Social, psychological and existential well-being in patients with glioma and their caregivers: a qualitative study

Temozolomide Versus Procarbazine, Lomustine, and Vincristine in Recurrent High-Grade Glioma

Do statins, ACE inhibitors or sartans improve outcome in primary glioblastoma?

Adjustment and support needs of glioma patients and their relatives: serial interviews

Radiotherapy for pituitary adenomas: Long-term efficacy and toxicity

Prospective audit showing improved patient-assessed skin toxicity with use of betamethasone cream for those at high risk of radiation dermatitis

International comparisons of survival from lung cancer: pitfalls and warnings

Glioblastoma and the search for non-hypothesis driven combination therapeutics in academia

Portal imaging to assess set-up errors, tumor motion and tumor shrinkage during conformal radiotherapy of non-small cell lung cancer

Results of the interim analysis of the EORTC randomized phase III CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p/19q co-deletion: An Intergroup trial

Long-term neurocognitive and other side effects of radiotherapy, with or without chemotherapy, for glioma

What will be the radiotherapy machine capacity required for optimal delivery of radiotherapy in Scotland in 2015?

Improved survival from lung cancer in British Columbia compared to Scotland—Are different treatment rates the whole story?

"It changes everything": Understanding how people experience the impact of living with a lower-grade glioma

Brain tumor research in the United Kingdom: current perspective and future challenges. A strategy document from the NCRI Brain Tumor CSG

Mental incapacity in patients undergoing neuro-oncologic treatment: a cross-sectional study

Thoracic radiotherapy for limited-stage small cell lung cancer: Issues of timing, volumes, dose, and fractionation

Suchergebnisse filtern